Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2015 Filed Feb 6, 2015 22:43 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,300 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001209191-15-010444 · doc4.xml · derivative · entry 10 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,400 Underlying: Common Stock · 1,300 shares Expires 2015-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| February 04, 2015 Filed Feb 6, 2015 22:43 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 700 | $110.15 | $77,105.00 |
DisclosureSEC source: 0001209191-15-010444 · doc4.xml · nonDerivative · entry 7 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,895 F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $110.15 (range $109.81 to $110.56). Read SEC document |
| February 04, 2015 Filed Feb 6, 2015 22:43 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 3,700 | $109.30 | $404,410.00 |
DisclosureSEC source: 0001209191-15-010444 · doc4.xml · nonDerivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,595 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $109.30 (range $108.78 to $109.77). Read SEC document |
| February 04, 2015 Filed Feb 6, 2015 22:43 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 500 | $108.18 | $54,090.00 |
DisclosureSEC source: 0001209191-15-010444 · doc4.xml · nonDerivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,295 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $108.18 (range $107.55 to $108.41). Read SEC document |
| February 04, 2015 Filed Feb 6, 2015 22:43 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 300 | $106.51 | $31,953.00 |
DisclosureSEC source: 0001209191-15-010444 · doc4.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,795 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $106.51 (range $106.14 to $106.76). Read SEC document |
| February 04, 2015 Filed Feb 6, 2015 22:43 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 500 | $105.34 | $52,670.00 |
DisclosureSEC source: 0001209191-15-010444 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,095 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $105.34 (range $104.86 to $105.70). F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2015 Filed Feb 6, 2015 22:43 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 4,400 | $35.64 | $156,816.00 |
DisclosureSEC source: 0001209191-15-010444 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2015 Filed Feb 6, 2015 22:43 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 1,300 | $17.16 | $22,308.00 |
DisclosureSEC source: 0001209191-15-010444 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2015 Filed Feb 4, 2015 21:53 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionStock Option (right to buy) · Derivative | 938 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · derivative · entry 12 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 938 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| February 03, 2015 Filed Feb 4, 2015 21:53 UTC |
Silva Paul MSVP & Corp Controller
|
SaleCommon Stock | 100 | $111.32 | $11,132.00 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 9 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,187 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 03, 2015 Filed Feb 4, 2015 21:53 UTC |
Silva Paul MSVP & Corp Controller
|
SaleCommon Stock | 100 | $109.50 | $10,950.00 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 8 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,287 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 03, 2015 Filed Feb 4, 2015 21:53 UTC |
Silva Paul MSVP & Corp Controller
|
SaleCommon Stock | 300 | $108.16 | $32,448.00 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,387 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $108.16 (range $108.03 to $108.40). Read SEC document |
| February 03, 2015 Filed Feb 4, 2015 21:53 UTC |
Silva Paul MSVP & Corp Controller
|
SaleCommon Stock | 438 | $107.04 | $46,883.52 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,687 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $107.04 (range $106.77 to $107.45). Read SEC document |
| February 03, 2015 Filed Feb 4, 2015 21:53 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionCommon Stock | 938 | $38.80 | $36,394.40 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:01 UTC |
Chodakewitz JeffreyEVP GMDA, CMO
|
GrantStock Option (right to buy) · Derivative | 57,500 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-15-009877 · doc4.xml · derivative · entry 2 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2025-02-02 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2015. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:01 UTC |
Chodakewitz JeffreyEVP GMDA, CMO
|
GrantCommon Stock | 17,250 | $0.01 | $172.50 |
DisclosureSEC source: 0001209191-15-009877 · doc4.xml · nonDerivative · entry 1 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,562 F1 · shares: Performance-based restricted stock award that will vest as to (i) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales in the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results of a clinical trial establishing proof-of-concept for a next generation CFTR corrector and (ii) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales outside of the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results from a successful pivotal clinical trial for a non-cystic fibrosis drug candidate sufficient to support the filing of an NDA. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:07 UTC |
SMITH IAN FEVP & CFO
|
GrantStock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-15-009887 · doc4.xml · derivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2025-02-02 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2015. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:07 UTC |
SMITH IAN FEVP & CFO
|
GrantCommon Stock | 20,700 | $0.01 | $207.00 |
DisclosureSEC source: 0001209191-15-009887 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,526 F1 · shares: Performance-based restricted stock award that will vest as to (i) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales in the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results of a clinical trial establishing proof-of-concept for a next generation CFTR corrector and (ii) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales outside of the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results from a successful pivotal clinical trial for a non-cystic fibrosis drug candidate sufficient to support the filing of an NDA. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:09 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-15-009890 · doc4.xml · derivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2025-02-02 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2015. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:09 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
GrantCommon Stock | 20,700 | $0.01 | $207.00 |
DisclosureSEC source: 0001209191-15-009890 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,270 F1 · shares: Performance-based restricted stock award that will vest as to (i) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales in the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results of a clinical trial establishing proof-of-concept for a next generation CFTR corrector and (ii) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales outside of the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results from a successful pivotal clinical trial for a non-cystic fibrosis drug candidate sufficient to support the filing of an NDA. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantStock Option (right to buy) · Derivative | 213,000 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-15-009892 · doc4.xml · derivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,000 Underlying: Common Stock · 213,000 shares Expires 2025-02-02 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2015. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantCommon Stock | 64,500 | $0.01 | $645.00 |
DisclosureSEC source: 0001209191-15-009892 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,177 F1 · shares: Performance-based restricted stock award that will vest as to (i) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales in the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results of a clinical trial establishing proof-of-concept for a next generation CFTR corrector and (ii) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales outside of the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results from a successful pivotal clinical trial for a non-cystic fibrosis drug candidate sufficient to support the filing of an NDA. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:15 UTC |
Sachdev AmitEVP, Policy, Access & Value
|
GrantStock Option (right to buy) · Derivative | 57,500 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-15-009898 · doc4.xml · derivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2025-02-02 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2015. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:15 UTC |
Sachdev AmitEVP, Policy, Access & Value
|
GrantCommon Stock | 17,250 | $0.01 | $172.50 |
DisclosureSEC source: 0001209191-15-009898 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Policy, Access & Value 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,921 F1 · shares: Performance-based restricted stock award that will vest as to (i) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales in the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results of a clinical trial establishing proof-of-concept for a next generation CFTR corrector and (ii) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales outside of the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results from a successful pivotal clinical trial for a non-cystic fibrosis drug candidate sufficient to support the filing of an NDA. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:18 UTC |
Silva Paul MSVP & Corp Controller
|
GrantStock Option (right to buy) · Derivative | 20,625 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-15-009903 · doc4.xml · derivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,625 Underlying: Common Stock · 20,625 shares Expires 2025-02-02 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2015. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:18 UTC |
Silva Paul MSVP & Corp Controller
|
GrantCommon Stock | 6,875 | $0.01 | $68.75 |
DisclosureSEC source: 0001209191-15-009903 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,062 F1 · shares: Performance-based restricted stock award that will vest as to (i) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales in the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results of a clinical trial establishing proof-of-concept for a next generation CFTR corrector and (ii) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales outside of the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results from a successful pivotal clinical trial for a non-cystic fibrosis drug candidate sufficient to support the filing of an NDA. Read SEC document |
| February 02, 2015 Filed Feb 4, 2015 21:51 UTC |
Chodakewitz JeffreyEVP GMDA, CMO
|
SaleCommon Stock | 100 | $110.85 | $11,085.00 |
DisclosureSEC source: 0001209191-15-009464 · doc4.xml · nonDerivative · entry 3 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,312 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 02, 2015 Filed Feb 4, 2015 21:51 UTC |
Chodakewitz JeffreyEVP GMDA, CMO
|
SaleCommon Stock | 788 | $109.80 | $86,522.40 |
DisclosureSEC source: 0001209191-15-009464 · doc4.xml · nonDerivative · entry 2 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,412 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $109.80 (range $109.42 to $110.37). Read SEC document |
| February 02, 2015 Filed Feb 4, 2015 21:51 UTC |
Chodakewitz JeffreyEVP GMDA, CMO
|
SaleCommon Stock | 300 | $108.64 | $32,592.00 |
DisclosureSEC source: 0001209191-15-009464 · doc4.xml · nonDerivative · entry 1 Chodakewitz Jeffrey · CIK 0001610876 · EVP GMDA, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,200 F1 · kind: Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $108.64 (range $108.30 to $109.24). F3 · price: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2015 Filed Feb 4, 2015 21:53 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · derivative · entry 11 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 1,125 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2015 Filed Feb 4, 2015 21:53 UTC |
Silva Paul MSVP & Corp Controller
|
SaleCommon Stock | 157 | $110.76 | $17,389.32 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,187 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $110.76 (range $110.74 to $110.80). Read SEC document |
| February 02, 2015 Filed Feb 4, 2015 21:53 UTC |
Silva Paul MSVP & Corp Controller
|
SaleCommon Stock | 668 | $109.89 | $73,406.52 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,344 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $109.89 (range $109.51 to $110.42). Read SEC document |
| February 02, 2015 Filed Feb 4, 2015 21:53 UTC |
Silva Paul MSVP & Corp Controller
|
SaleCommon Stock | 300 | $108.11 | $32,433.00 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,012 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $108.11 (range $107.94 to $108.22). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2015 Filed Feb 4, 2015 21:53 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionCommon Stock | 1,125 | $37.86 | $42,592.50 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:17 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,400 | $0.00 Strike: $35.64 | $0.00 |
DisclosureSEC source: 0001209191-15-007866 · doc4.xml · derivative · entry 11 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,600 Underlying: Common Stock · 4,400 shares Expires 2016-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:17 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,300 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001209191-15-007866 · doc4.xml · derivative · entry 10 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,700 Underlying: Common Stock · 1,300 shares Expires 2015-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:17 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,988 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0001209191-15-007866 · doc4.xml · derivative · entry 9 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,988 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:17 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 1,300 | $124.13 | $161,369.00 |
DisclosureSEC source: 0001209191-15-007866 · doc4.xml · nonDerivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,895 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $124.13 (range $123.66 to $124.59). Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:17 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 4,986 | $123.14 | $613,976.04 |
DisclosureSEC source: 0001209191-15-007866 · doc4.xml · nonDerivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,195 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $123.14 (range $122.65 to $123.49). Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:17 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 4,402 | $121.97 | $536,911.94 |
DisclosureSEC source: 0001209191-15-007866 · doc4.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,181 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $121.97 (range $121.41 to $122.40). F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:17 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 4,400 | $35.64 | $156,816.00 |
DisclosureSEC source: 0001209191-15-007866 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:17 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 1,300 | $17.16 | $22,308.00 |
DisclosureSEC source: 0001209191-15-007866 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:17 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 4,988 | $10.41 | $51,925.08 |
DisclosureSEC source: 0001209191-15-007866 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2015 Filed Jan 28, 2015 22:39 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-15-007111 · doc4.xml · derivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 1,125 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/25/2012. Read SEC document |
| January 26, 2015 Filed Jan 28, 2015 22:39 UTC |
Silva Paul MSVP & Corp Controller
|
SaleCommon Stock | 400 | $126.27 | $50,508.00 |
DisclosureSEC source: 0001209191-15-007111 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,187 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $126.27 (range $126.00 to $126.56). Read SEC document |
| January 26, 2015 Filed Jan 28, 2015 22:39 UTC |
Silva Paul MSVP & Corp Controller
|
SaleCommon Stock | 725 | $125.26 | $90,813.50 |
DisclosureSEC source: 0001209191-15-007111 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,587 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $125.26 (range $124.99 to $125.83). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2015 Filed Jan 28, 2015 22:39 UTC |
Silva Paul MSVP & Corp Controller
|
Exercise / conversionCommon Stock | 1,125 | $48.74 | $54,832.50 |
DisclosureSEC source: 0001209191-15-007111 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2015 Filed Jan 23, 2015 22:12 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,400 | $0.00 Strike: $35.64 | $0.00 |
DisclosureSEC source: 0001209191-15-006252 · doc4.xml · derivative · entry 10 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,000 Underlying: Common Stock · 4,400 shares Expires 2016-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| January 21, 2015 Filed Jan 23, 2015 22:12 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,300 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001209191-15-006252 · doc4.xml · derivative · entry 9 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 1,300 shares Expires 2015-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| January 21, 2015 Filed Jan 23, 2015 22:12 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,800 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0001209191-15-006252 · doc4.xml · derivative · entry 8 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,988 Underlying: Common Stock · 4,800 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.